Sarepta Therapeutics, Inc. $SRPT Shares Bought by Aberdeen Group plc

Aberdeen Group plc boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,982,764 shares of the biotechnology company’s stock after acquiring an additional 740,360 shares during the quarter. Aberdeen Group plc owned about 2.03% of Sarepta Therapeutics worth $38,208,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Public Sector Pension Investment Board bought a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $7,345,000. Prospera Financial Services Inc bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $281,000. Profund Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 22.3% during the third quarter. Profund Advisors LLC now owns 38,874 shares of the biotechnology company’s stock valued at $749,000 after acquiring an additional 7,085 shares during the period. Savant Capital LLC acquired a new position in Sarepta Therapeutics in the third quarter valued at about $439,000. Finally, Atlantic Union Bankshares Corp bought a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $48,000. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $17.79 on Tuesday. The firm has a market capitalization of $1.86 billion, a P/E ratio of -5.91, a P/E/G ratio of 0.45 and a beta of 0.39. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $111.21. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The company’s 50 day moving average price is $21.03 and its two-hundred day moving average price is $20.19.

Analysts Set New Price Targets

SRPT has been the topic of several research reports. Wells Fargo & Company cut their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Piper Sandler upped their price objective on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Finally, Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.